Chemoprevention of breast cancer: recommendations and rationale.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000209:etiology
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride